biotech news today obesity drugs glp-1 The race may have a new contender. π Regeneron reported Phase 3 data showing its drug candidate delivered up to 19.3% weight loss at 48 weeks, approaching the efficacy seen Lilly is now pharma's top
Description
During this period, discussions around microdosing GLP-1 began circulating on social media and online forums
An experimental study of exenatide effects on renal injury in diabetic rats1
For patients with pre-existing mild or moderate DR, the effects of GLP-1 drugs could significantly worsen this condition
These fats are also great for supporting your overall health
The judge has not yet made a decision on Eli Lillys request to dismiss the lawsuits or keep the plaintiffs experts out of trial
Kipnis adds
